Order Total PSA First, Then Add Free PSA Selectively
You should routinely order total PSA for screening and monitoring, and add free PSA (percent free PSA) only in specific clinical scenarios—primarily when total PSA is in the 4-10 ng/mL range with a normal DRE, or when considering whether to proceed with biopsy after an initial negative result.
When to Order Each Test
Total PSA: The Primary Screening Test
- Always start with total PSA for initial screening and routine monitoring 1
- Total PSA alone is sufficient for:
- Annual screening in appropriate candidates
- Follow-up after negative biopsies when PSA remains <4 ng/mL
- Monitoring PSA velocity over time
Free PSA: A Reflex Test for Specific Situations
Order percent free PSA when:
Total PSA is 4-10 ng/mL with normal DRE (the "diagnostic gray zone") 2
- This is the FDA-approved indication
- Helps decide whether to proceed with initial biopsy
- A 25% free PSA cutoff detected 95% of cancers while avoiding 20% of unnecessary biopsies 2
After a negative biopsy with persistently elevated PSA 1
- Helps determine need for repeat biopsy
- Use alongside total PSA for 6-12 month follow-up
Total PSA 2.6-4 ng/mL in selected circumstances 1
- NCCN notes free PSA is "not generally used" for initial biopsy decisions below 4 ng/mL
- However, may be considered in high-risk patients (family history, African American)
Interpretation Thresholds
Percent Free PSA cutoffs 1:
- <10%: Strongly suspicious—proceed with biopsy
- 10-25%: Indeterminate—consider biopsy based on other risk factors
- >25%: Lower suspicion—may defer biopsy
Recent evidence suggests these cutoffs remain valid even at lower PSA ranges (2-4 ng/mL), where a free PSA <15-20% identifies clinically significant cancers 3, 4.
Clinical Algorithm
Step 1: Measure total PSA
- If <2.5 ng/mL with normal DRE → annual follow-up with total PSA only
- If 2.6-4 ng/mL → consider risk factors; may add free PSA in high-risk patients
- If 4-10 ng/mL with normal DRE → add free PSA to guide biopsy decision
- If >10 ng/mL → proceed to biopsy regardless of free PSA 1
Step 2: If free PSA ordered, interpret with total PSA
- Calculate percent free PSA (free/total × 100)
- Apply cutoffs above
- Consider other factors: age, prostate volume, family history, ethnicity
Important Caveats
Free PSA is NOT a first-line screening test 1. The NCCN explicitly states: "Free PSA is not generally used in deciding whether or not to perform an initial biopsy" 1.
Laboratory considerations:
- Free PSA has greater sample instability than total PSA 5
- Requires same-day processing or proper storage
- Assay standardization varies between laboratories
- Always use the same laboratory for serial measurements
Factors affecting both tests:
- Ejaculation within 48 hours (repeat if marginally elevated) 1
- Finasteride/dutasteride (lowers PSA ~50%) 1, 6
- Prostatitis (can cause dramatic PSA elevations)
- Recent prostate biopsy (wait 3-6 weeks) 7
Cost-Effectiveness Consideration
Adding free PSA reflexively to all total PSA tests is not cost-effective. The diagnostic benefit is concentrated in the 4-10 ng/mL range where it meaningfully reduces unnecessary biopsies 8, 9. Below 4 ng/mL, the incremental benefit is modest and should be reserved for patients where clinical suspicion remains high despite the lower PSA 9, 4.
Bottom line: Order total PSA routinely; add free PSA selectively when total PSA is 4-10 ng/mL with normal DRE, or when deciding about repeat biopsy after initial negative results. This targeted approach maximizes diagnostic yield while minimizing unnecessary testing and biopsies.